ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Edaravone

Also written as “MT-1186”, “MCI-186” and “Continuous infusion high-dose MCI-186”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Ischemic Stroke · Cerebral Infarction · Renal Insufficiency · Ischemia, led by 4 companies.

Drug pageEdaravone: every studyAll 38 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 12, 200526 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogi230 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Jiangsu HengRui Medicineits history only10 open or runningphase 1since Jul 16, 2025Jul 16, 2025none ahead
Nanjing Yoko Biomedicalits history only10 open or runningphase 1since Dec 17, 2019Dec 17, 2019none ahead
Shanghai Auzone Biological Technologyits history only10 open or runningphase 1since Oct 16, 2023Oct 16, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Shionogi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Sep 12, 2005.

  1. Dec 11, 2011Phase 3 study in Amyotrophic Lateral SclerosisNCT01492686 · 137 enrolled · Japan
  2. Sep 19, 20172 phase 1 studiesNCT03289234, NCT03289208
  3. Nov 2, 2017Phase 2 study in Ischemic StrokeNCT03346538 · 17 enrolled · Japan
  4. Aug 27, 2018Phase 1 study in Severe Hepatic ImpairmentNCT03664544 · 12 enrolled · Czechia, Hungary, Slovakia
  5. Jul 10, 2019Phase 1 study in Healthy Adult SubjectsNCT04029090 · 27 enrolled · Japan
  6. Nov 13, 2019Phase 3 study in ALSNCT04165824 · 185 enrolled · United States, Canada, France and more
  7. Nov 22, 2019Phase 1 study in Japanese Patients With ALSNCT04176224 · 9 enrolled · Japan
  8. Jan 23, 2020Phase 1 study in Japanese Patients With ALSNCT04254913 · 6 enrolled · Japan
  9. Jul 17, 20203 phase 1 studies in Healthy Adult SubjectsNCT04481789, NCT04481750, NCT04493281
  10. Sep 23, 20202 phase 3 studiesNCT04569084, NCT04577404
  11. Feb 25, 2021Phase 1 study in Healthy Adult SubjectsNCT04776135 · 36 enrolled · Japan
  12. Nov 28, 2021Phase 3 study in ALSNCT05151471 · 202 enrolled · United States, Canada, Germany and more
  13. Apr 19, 2022Phase 1 study in Healthy Adult SubjectsNCT05342597 · 16 enrolled · Japan
  14. Oct 2, 2022Phase 3 study in ALSNCT05568615 · 15 enrolled · Japan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 23 Shionogi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05568615ALS · Japan3CompletedJun 27, 202315
NCT05342597Healthy Adult Subjects · Japan1CompletedJul 24, 201916
NCT05151471ALS · United States, Canada, Germany and more3TerminatedSep 29, 2023202
NCT04776135Healthy Adult Subjects · Japan1CompletedApr 1, 202136
NCT04577404Amyotrophic Lateral Sclerosis · United States, Canada, France and more3CompletedAug 9, 2023124
NCT04569084ALS · United States, Canada, Germany and more3TerminatedSep 29, 2023384
NCT04493281Healthy Adult Subjects · Japan1CompletedApr 21, 201942
NCT04481789Healthy Adult Subjects · Japan1CompletedDec 20, 201884
NCT04481750Healthy Adult Subjects · Japan1CompletedAug 3, 201874
NCT04254913Japanese Patients With ALS · Japan1CompletedApr 16, 20206
NCT04176224Japanese Patients With ALS · Japan1CompletedSep 4, 20199
NCT04165824ALS · United States, Canada, France and more3CompletedOct 7, 2021185
NCT04029090Healthy Adult Subjects · Japan1CompletedOct 20, 201827
NCT03664544Severe Hepatic Impairment · Czechia, Hungary, Slovakia1CompletedMar 25, 201912
NCT03346538Ischemic Stroke · Japan2TerminatedMay 14, 201817
NCT03289234Hepatic Impairment · Japan1CompletedJul 20, 201822
NCT03289208Renal Insufficiency · Japan1CompletedApr 16, 201830
NCT01492686Amyotrophic Lateral Sclerosis · Japan3CompletedSep 30, 2014137
NCT00821821Ischemic Stroke · Finland, Netherlands, United Kingdom2CompletedNov 30, 201036
NCT00424463Amyotrophic Lateral Sclerosis · Japan3CompletedMay 31, 2009181
NCT00415519Amyotrophic Lateral Sclerosis3CompletedJul 31, 200825
NCT00330681Amyotrophic Lateral Sclerosis3CompletedSep 30, 2008206
NCT00200356Cerebral Infarction4CompletedOct 31, 2006401

How it is read

Names in the registry

  • “MT-1186”, 12 entries
  • “MCI-186”, 10 entries
  • “Edaravone”, 1 entry
  • “Continuous infusion high-dose MCI-186”, 1 entry
  • “Continuous infusion low-dose MCI-186”, 1 entry

Codes read as this program: MT1186, MCI186.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.